Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's D&A?
- Aurinia Pharmaceuticals (AUPH) reported D&A of $4.83M in Q2 2026.
- How has Aurinia Pharmaceuticals's D&A changed year-over-year?
- Aurinia Pharmaceuticals's D&A decreased by 0.6% year-over-year, from $4.86M to $4.83M.
- What is the long-term trend for Aurinia Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's D&A has grown at a 74.5% compound annual growth rate (CAGR), from $2.1M to $19.45M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Aurinia Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude